Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes

• Status: Completed
• Trial end date: 2004-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to test if Insulin Detemir as add-on to current Oral Antidiabetic Drug treatment is at least as effective as Insulin Glargine as add-on to current Oral Antidiabetic Drug treatment in reducing HbA1c in patients with Type 2 Diabetes.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Hypoglycemic Agents; Insulin; Insulin Detemir; Insulin Glargine; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Type 2 Diabetes for more than 12 months, and no previous insulin treatment

• Oral Antidiabetic Drug treatment for at least 4 months

• Body Mass Index (BMI) less than 40 kg/m2

• HbA1c 7.5-10.0%

Exclusion Criteria:

• Current or previous treatment with thiazolidinediones within the last 6 months

• Oral Antidiabetic Drug treatment with combination of three or more Oral Antidiabetic Drugs within the last 6 months

• Proliferative retinopathy or maculopathy

• Known hypoglycaemia unawareness